1.Study on the potential mechanism of SMXBT in the treatment of AECOPD by network pharmacology and molecular docking
Liangshan LIU ; Zhiyao BAO ; Liuhui SHI ; Hua NIAN ; Minghua MA ; Zhenwei WANG
Journal of Pharmaceutical Practice and Service 2026;44(3):144-151
Objective To explore the potential molecular mechanism of Sangma Xingbei Tang (SMXBT) in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods TCMSP and TCMID databases were searched for the active ingredients of SMXBT, the targets of the active ingredients were predicted by SwissTargetPrediction database, and the AECOPD-related targets were searched by GeneCards and OMIM databases; the drug-active ingredient-target network and protein interaction network were constructed, and the GO enrichment and KEGG pathway enrichment were analyzed by the DAVID database. The drug-active ingredient-target network and protein interaction network were constructed, and the GO enrichment and KEGG pathway enrichment were analyzed by DAVID database, and molecular docking was performed by AutoDock Tools software. Animal experiments were conducted for validation. Results 192 active ingredients were obtained and
2.A survey of transfusion medicine knowledge among pediatricians/postgraduates and an evaluation of large language models for learning assistance
Haiting LIU ; Xueyuan HUANG ; Minghua YANG ; Qiushi WANG ; Rong HUANG ; Rong GUI
Chinese Journal of Blood Transfusion 2026;39(3):329-338
Objective: To investigate the current knowledge status of transfusion medicine among pediatricians/postgraduates and the reliability of large language models (LLMs) for assisted learning, and to assess changes in pediatricians' transfusion medicine knowledge before and after the implementation of the "Pediatric Transfusion Guideline" (hereafter referred to as the "Guideline"). Methods: In January 2022 (prior to the implementation of the "Guideline"), a questionnaire was developed based on the "Guideline" content and distributed to pediatricians. Subsequently, in July 2025 (after the implementation of the "Guideline"), the "Pediatric Transfusion Medicine Knowledge Questionnaire" was designed based on the content of the January 2022 questionnaire. This questionnaire survey was conducted on pediatricians/postgraduates and LLMs. We analyzed the level of transfusion medicine knowledge among pediatricians/postgraduates and the reliability of LLMs for assisted learning, and compared the accuracy of pediatricians' responses before and after "Guideline" implementation. Results: The survey results after the implementation of the "Guidelines" revealed that pediatricians/postgraduates achieved response accuracy rates exceeding 80% on the topic of "Patient Blood Management". However, response accuracy rates were below 30% for topics including "Types and Indications of Blood Components/Products" and "E-valuation of Transfusion Efficacy". The pediatricians' accuracy rates for related questions before and after the implementation of the "Guidelines" were 14.7%-68.9% and 3%-38%, respectively, and the comparison of accuracy rates for each question showed significant differences (P<0.001). The accuracy rates of the LLMs on the questionnaire were all below 90%. Among them, Doubao (81.1%) and Kimi (86.4%) achieved relatively higher accuracy rates, while Tencent Yuanbao (Hunyuan) had the lowest accuracy rate at only 59.5%. Conclusion: The implementation of the "Guideline" may have improved pediatricians' knowledge level of pediatric transfusion medicine. However, their knowledge level of pediatric transfusion remains low, and LLMs cannot yet provide absolutely reliable guidance. Systematic training in pediatric transfusion medicine is urgently needed.
3.Discussion on the Correlation between Qi Deficiency Constitution and Allergic Diseases
Gengshuo MIAO ; Minghua BAI ; Cangmei LIU ; Siying DONG ; Ji WANG
Journal of Traditional Chinese Medicine 2025;66(15):1522-1527
Based on clinical epidemiological data, it is believed that qi deficiency constitution is closely related to allergic diseases. According to the fundamental principles of traditional Chinese medicine (TCM) constitution theory, the intrinsic connection between qi deficiency constitution and allergic diseases is analyzed from the perspectives of inherited endowment, life process, environmental restriction, and the interplay of form and spirit. This paper discusses the key points of regulating qi deficiency constitution to prevent allergic diseases in three stages, prevention before illness, prevention of disease progression, and prevention of recurrence after recovery. It also distinguishes the treatment directions for regulating qi deficiency constitution to treat allergic diseases based on different disease locations such as the lung, spleen, and kidney. This aims to expand new ideas for the research on qi deficiency constitution and allergic diseases as well as the prevention and treatment of allergic diseases.
4.NIP7 upregulates the expression of ubiquitin-conjugating enzyme E2 C to promote tumor growth in anaplastic thyroid cancer.
Yingying GONG ; Ziwen FANG ; Yixuan WANG ; Minghua GE ; Zongfu PAN
Journal of Zhejiang University. Medical sciences 2025;54(3):372-381
OBJECTIVES:
To investigate the role of nucleolar pre-rRNA processing protein NIP7 (NIP7) in maintaining the malignant phenotype of anaplastic thyroid cancer (ATC) and its molecular mechanisms.
METHODS:
NIP7 expression in ATC tissues and its gene knock-out effects in ATC cells were analyzed using gene expression microarray (GSE33630), proteome database (IPX0008941000) and the Dependency Map database, respectively. Expression and localization of NIP7 in normal thyroid cells, papillary thyroid cancer cells, and ATC cells were detected by Western blotting. Small interfering RNA (siRNA) was transfected into ATC cells, and the knockdown efficiency of NIP7 was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting. Cell proliferation was assessed by CCK-8 assay, colony formation was evaluated by colony formation assay, and tumor growth was assessed by xenograft tumor model in nude mice. SUnSET (surface sensing of translation) assay combined with co-immunoprecipitation were employed to evaluate the effect of NIP7 silencing on ubiquitin-conjugating enzyme E2 C (UBE2C) translation. Finally, gene set enrichment analysis was used to identify shared pathways of NIP7 and UBE2C, which were validated by qRT-PCR.
RESULTS:
Compared with normal tissues and papillary thyroid cancer, NIP7 was significantly upregulated in ATC tissues, and had a gene knock-out fitness effect on different ATC cell lines. The relative protein levels of NIP7 in ATC cells were significantly higher than those in normal thyroid follicular cells, and the protein was mainly expressed in the nucleus. NIP7 silencing significantly inhibited cell proliferation and reduced colony formation. Xenograft tumor model showed that NIP7 knockdown significantly slowed down the growth of ATC xenograft, and the tumor volume and weight were significantly lower than those in the control group (all P<0.05). NIP7 silencing downregulated the protein level of UBE2C, but did not affect the expression of UBE2C mRNA. Compared to the control group, UBE2C silencing significantly inhibited ATC cells proliferation (P<0.01) and colony formation (P<0.05). UBE2C overexpression reversed the proliferation-inhibitory effect induced by NIP7 silencing (P<0.01). Gene set enrichment analysis indicated that NIP7 and UBE2C were both involved in DNA replication. NIP7 or UBE2C silencing could significantly downregulate the expression levels of DNA polymerase epsilon, catalytic subunit 2 and replication factor C4 in DNA replication pathway.
CONCLUSIONS
NIP7 promotes ATC tumor growth by upregulating UBE2C to mediate DNA replication.
Humans
;
Ubiquitin-Conjugating Enzymes/genetics*
;
Thyroid Neoplasms/genetics*
;
Thyroid Carcinoma, Anaplastic/genetics*
;
Animals
;
Mice, Nude
;
Mice
;
Cell Line, Tumor
;
Cell Proliferation
;
Up-Regulation
;
RNA, Small Interfering/genetics*
;
Nuclear Proteins/metabolism*
;
Gene Expression Regulation, Neoplastic
5.An infant with leukemia complicated by Pneumocystisjirovecii pneumonia: A case report and literature review.
Zhijuan ZHANG ; Hong ZHENG ; Shengfeng WANG ; Shan ZHU ; Minghua YANG
Journal of Central South University(Medical Sciences) 2025;50(6):1106-1112
Pneumocystis jirovecii pneumonia (PJP) is an opportunistic pulmonary infection that commonly occurs in immunocompromised children. We report a case of infantile leukemia complicated by PJP and review the relevant literature. A summary and analysis of 10 infantile leukemia patients with PJP infection (9 cases reported in the literature and 1 case from our center) showed that PJP mostly occurred in the early stages of chemotherapy (80%, 8/10). The main clinical manifestations were dyspnea (100%, 10/10) and hypoxemia (50%, 5/10), while pulmonary imaging findings lacked specificity. In most cases (50%, 5/10), diagnosis was established by identifying pathogens in bronchoalveolar lavage fluid under microscopy. In our case, diagnosis was confirmed using targeted next-generation sequencing (tNGS) of bronchoalveolar lavage fluid. Treatment with intravenous sulfamethoxazole complex was administered in 8 patients, all of whom eventually recovered. PJP may occur in the early stages of chemotherapy for infantile leukemia, thus early prevention is necessary. tNGS facilitates early diagnosis of PJP, and sulfamethoxazole complex remains an effective therapeutic option.
Humans
;
Infant
;
Bronchoalveolar Lavage Fluid/microbiology*
;
Immunocompromised Host
;
Leukemia/complications*
;
Pneumocystis carinii/isolation & purification*
;
Pneumonia, Pneumocystis/diagnosis*
;
Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use*
6.Erratum: Author correction to "The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAP via ER stress in pancreatic cancer cells" Acta Pharm Sin B 12 (2022) 210-227.
Junxia WANG ; Minghua CHEN ; Mengyan WANG ; Wenxia ZHAO ; Conghui ZHANG ; Xiujun LIU ; Meilian CAI ; Yuhan QIU ; Tianshu ZHANG ; Huimin ZHOU ; Wuli ZHAO ; Shuyi SI ; Rongguang SHAO
Acta Pharmaceutica Sinica B 2025;15(2):1208-1209
[This corrects the article DOI: 10.1016/j.apsb.2021.07.004.].
7.Arsenic trioxide-based nanoparticles for enhanced chemotherapy by activating pyroptosis.
Shengmei WANG ; Ding MA ; Minghua YANG ; Ye ZHANG ; Shengfeng WANG ; Wenhu ZHOU
Acta Pharmaceutica Sinica B 2025;15(11):6001-6018
Chemotherapy remains a primary treatment option for hepatocellular carcinoma (HCC), yet its clinical benefits are often unsatisfactory. Utilizing arsenic trioxide (ATO) as a model, this study elucidates the role of autophagy inhibition in modulating the cellular response to chemotherapy, shifting cell death from apoptosis to pyroptosis via the caspase-3-GSDME pathway, thereby augmenting the anti-tumor efficacy. Building upon these findings, an ATO nanomedicine delivery system capable of autophagy inhibition to promote pyroptosis for enhanced tumor treatment was developed. Folic acid-modified albumin served as the stabilizer for nano self-assemblies formed through ion pairing between Mn2+ and ATO, encapsulating DNAzyme (Dz) targeting Beclin 1, a key autophagy regulator. Characterization studies confirmed efficient encapsulation of ATO and Dz within nanoparticles, designed to disintegrate in the intracellular microenvironment, releasing the all-active components, i.e., ATO, Mn2+, and Dz. Mn2+ acted as a metal cofactor to activate Dz for Beclin 1 mRNA cleavage, inhibiting autophagy and augmenting ATO-induced cell pyroptosis. Elevated cell pyroptosis levels not only enhance ATO's direct tumor cell killing capacity but also trigger anti-tumor immune responses, synergistically enhancing efficacy. Upon intravenous injection, the nanomedicine accumulated in tumor tissue and targeted liver cancer cells. Compared to free ATO, the nanomedicine exhibited significantly improved in vivo anti-tumor effects, achieving a 100% 45-day survival rate in mice with favorable biosafety profiles. This study offers novel insights into tumor chemotherapy sensitization and presents a promising strategy for ATO nanoformulation development.
8.Establishment and application of a duplex TaqMan fluorescence quatitative PCR assay for Mycoplasma gallisepticum and Mycoplasma synovialis detection
Zhimin DONG ; Lili WANG ; Xiangxue TIAN ; Chao LU ; Li ZHANG ; Minghua YAN
Chinese Journal of Veterinary Science 2025;45(5):987-993,1025
To rapidly detect and differentiate Mycoplasma gallisepticum(MG)and Mycoplasma synovialis(MS),two sets of specific primers and TaqMan probes were designed in this study based on the conserved regions of the 16S rRNA gene of two pathogens in NCBI.A dual TaqMan fluorescence quantitative PCR method for simultaneous detection of MG and MS was established by optimizing the reaction conditions,and the specificity,sensitivity,repeatability,and reliability of the method were verified.The results showed that this method could specifically amplify MG and MS without cross reactivity with 21 pathogens.The sensitivity experiment results showed that the detection limits of this method for MG and MS were 5.40×10 1 copies/μL and 6.60 × 10 1 copies/μL,and the sensitivity was 10 to 100 times higher than that of known methods.In addition,the re-sults of repetitive experiments showed that the coefficient of variation within and between groups was less than 1%.Compared with the single PCR amplification method in NY/T 553-2015,the positive sample detection coincidence rate,negative sample detection coincidence rate,and total sample detection coincidence rate were all 100.00%,indicating the strong reliability of this method.Using this method to detect 84 suspected Mycoplasma infected chicken samples,the results showed that the MG positivity rate was 32.14%(27/84),the MS positivity rate was 22.62%(19/84),and the positivity rate of samples infected with MG and MS was 16.67%(14/84).Concurrent-ly,182 healthy chicken cloacal swab samples,118 healthy chicken nasal swab samples,and 74 chicken farm environmental samples were detected,and the results showed that all samples were positive for Mycoplasma.The above results indicate that this method can be applied to the detec-tion of various clinical samples.In summary,the method established in this study had the advanta-ges of high specificity,high sensitivity,and good reproducibility.It could be used for clinical differ-ential diagnosis,epidemiological investigation,and pathogen purification of MG and MS infections.
9.Research and Direction for Traditional Chinese Medicine Constitution Identification Technology
Haoran WU ; Xue LIANG ; Minghua BAI ; Yan ZHANG ; Qi WANG
World Science and Technology-Modernization of Traditional Chinese Medicine 2025;27(8):2101-2109
The identification of constitutional types in traditional Chinese medicine(TCM)is a crucial component in realizing the concept of"treatment before the onset of disease".In recent years,the"Constitution in Chinese Medicine Questionnaire"has been employed as a standardized tool and has achieved notable success in the field of TCM constitution identification.However,there remains scope for further enhancement of its validity and applicability.Techniques for identifying TCM constitutions based on multidimensional phenotypes continue to emerge,yet a universally applicable constitutional determination model has yet to be established.We propose three research and development directions:The self-assessment questionnaires,the non-invasive point-of-care testing models based on TCM constitution phenotype,and the multidimensional phenotype-based constitution identification platforms.By way of an example,we outline specific developmental ideas with a focus on TCM constitution identification technology based on the analysis of exhaled breath.
10.Analysis of clinicopathological characteristics and prognostic factors in young breast cancer patients
Shujuan JIN ; Xiaojing LIU ; Di MENG ; Si ZUO ; Yan BI ; Xiaowei HAN ; Wei WANG ; Minghua ZHU ; Feng LIANG
Cancer Research and Clinic 2025;37(4):268-272
Objective:To investigate the clinicopathological characteristics and prognostic influencing factors in young breast cancer patients.Methods:A retrospective case series study was conducted. The clinical data of 408 young patients with breast cancer in the Fifth Medical Center of Chinese PLA General Hospital from January 2005 to December 2020 were retrospectively analyzed. The clinical characteristics and prognostic influencing factors of patients were observed. The Kaplan-Meier method was used to analyze overall survival (OS) and disease-free survival (DFS) of patients. Univariate analysis of prognostic factors was conducted by using the log-rank test, and multivariate analysis was performed by using Cox proportional risk model.Results:The median age [ M ( Q1, Q3)] of 408 young female patients with breast cancer was 36 (33, 39) years; the 5-year OS and 5-year DFS rates were 89.9%, 84.0% of 387 breast cancer patients in early and middle stage (except for stage Ⅳ). There were statistically significant differences in the 5-year OS and 5-year DFS rates (excluding stage Ⅳ of DFS) of patients with different clinical staging and molecular subtypes (all P < 0.05). The differences were statistically significant in the 5-year DFS rate of patients with different pathological types and histological grades (all P < 0.05). There were no statistically significant differences in the 5-year OS and DFS rates between the patients receiving breast-conserving surgery or mastectomy (all P > 0.05). The results of multivariate Cox regression analysis indicated that clinical staging ( HR = 3.121, 95% CI: 2.301-4.233, P < 0.001) and molecular classification ( HR = 1.441, 95% CI: 1.126-1.845, P = 0.004) were independent prognostic factors for OS. Additionally, clinical staging ( HR = 3.001, 95% CI: 2.174-4.141, P < 0.001) was identified as an independent prognostic factor for DFS. Conclusions:The prognosis of young breast cancer patients is closely related to clinical staging and molecular subtype. The later the clinical stage is, the poorer prognosis is. Luminal-type breast cancer has a better prognosis than other subtypes. For early-stage breast cancer patients who meet the criteria for breast-conserving surgery, breast-conserving surgery is the first-choice alternative.

Result Analysis
Print
Save
E-mail